2019年6月1日
An Open-label Clinical Study of Chronic L-theanine Supplementation in Patients with Major Depressive Disorder (P12-007-19)
Current Developments in Nutrition
- ,
- ,
- ,
- ,
- 巻
- 3
- 号
- Supplement_1
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1093/cdn/nzz035.p12-007-19
- 出版者・発行元
- Oxford University Press (OUP)
<title>Abstract</title>
<sec>
<title>Objectives</title>
The present study is designed to investigate the effectiveness of L-theanine (Suntheanine®) among patients with major depression disorder (MDD).
</sec>
<sec>
<title>Methods</title>
Twenty patients were recruited with moderate MDD (4 males; mean age: 41.0 ± 14.1 years, and 16 females; 42.9 ± 12.0 years) for this open-label clinical study. Participants were supplemented with L-theanine (250 mg/day) along with their current medication for 8 consecutive weeks. The cognitive functions and related symptoms were evaluated at baseline, 4 weeks, and 8 weeks after L-theanine supplementation using advanced version (21-items) of the Hamilton Depression Rating Scale (HAMD-21), Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), Brief Assessment of Cognition in Schizophrenia (BACS), including the Stroop test.
</sec>
<sec>
<title>Results</title>
L-theanine supplementation effectively lowered the HAMD-21 score (P = 0.007), and reduction was also observed in unremitted patients (HAMD-21 > 7; P = 0.004) at baseline. STAI test results indicated a significant decrease in Anxiety-trait scores (P = 0.012) after L-theanine supplementation. PSQI scores also decreased in the unremitted patients at baseline after L-theanine intake (P = 0.030). Concerning to the cognitive functions, response latency (P = 0.001) and error rate (P = 0.036) were lowered in the Stroop test, while executive function (P = 0.016) and verbal memory (P = 0.005) were significantly enhanced in the BACS test after L-theanine supplementation.
</sec>
<sec>
<title>Conclusions</title>
This study demonstrates that chronic L-theanine supplementation (8 weeks) is quite safe and features with diverse beneficial effects on the improvement of depressive symptoms, sleep disturbance, anxiety, and cognitive impairment functions in patients with MDD.
</sec>
<sec>
<title>Funding Sources</title>
This study was supported by an unrestricted research grant provided by the Taiyo Kagaku Co. Ltd.
</sec>
<sec>
<title>Objectives</title>
The present study is designed to investigate the effectiveness of L-theanine (Suntheanine®) among patients with major depression disorder (MDD).
</sec>
<sec>
<title>Methods</title>
Twenty patients were recruited with moderate MDD (4 males; mean age: 41.0 ± 14.1 years, and 16 females; 42.9 ± 12.0 years) for this open-label clinical study. Participants were supplemented with L-theanine (250 mg/day) along with their current medication for 8 consecutive weeks. The cognitive functions and related symptoms were evaluated at baseline, 4 weeks, and 8 weeks after L-theanine supplementation using advanced version (21-items) of the Hamilton Depression Rating Scale (HAMD-21), Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), Brief Assessment of Cognition in Schizophrenia (BACS), including the Stroop test.
</sec>
<sec>
<title>Results</title>
L-theanine supplementation effectively lowered the HAMD-21 score (P = 0.007), and reduction was also observed in unremitted patients (HAMD-21 > 7; P = 0.004) at baseline. STAI test results indicated a significant decrease in Anxiety-trait scores (P = 0.012) after L-theanine supplementation. PSQI scores also decreased in the unremitted patients at baseline after L-theanine intake (P = 0.030). Concerning to the cognitive functions, response latency (P = 0.001) and error rate (P = 0.036) were lowered in the Stroop test, while executive function (P = 0.016) and verbal memory (P = 0.005) were significantly enhanced in the BACS test after L-theanine supplementation.
</sec>
<sec>
<title>Conclusions</title>
This study demonstrates that chronic L-theanine supplementation (8 weeks) is quite safe and features with diverse beneficial effects on the improvement of depressive symptoms, sleep disturbance, anxiety, and cognitive impairment functions in patients with MDD.
</sec>
<sec>
<title>Funding Sources</title>
This study was supported by an unrestricted research grant provided by the Taiyo Kagaku Co. Ltd.
</sec>
- リンク情報
- ID情報
-
- DOI : 10.1093/cdn/nzz035.p12-007-19
- eISSN : 2475-2991